Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab plus liposomal doxorubicin versus liposomal doxorubicin in relapsed advanced epithelial ovarian or primary peritoneal cancer
2007-000509-31Phase 2Completed
- Sponsor
- Biogen
- Start
- Jul 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Ovarian Epithelial Adenocarcinoma and primary peritoneal cancer (PPC) comparing Volociximab plus liposomal doxorubicin with Liposomal doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Jul 2007; status: completed.
02
Drugs
volociximabdoxorubicin
03
Conditions
Ovarian Epithelial Adenocarcinomaprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2007-000509-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000509-31.